Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone propionate/salmeterol versus fluticasone propionate in asthma over 52 weeks
2015-004883-12Phase 4
- Sponsor
- GSK
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in asthma comparing FSC DISKUS 250/50 mcg BID with FP DISKUS 250 mcg BID (2 arms). Primary endpoint: Mean change from baseline in pre-dose FEV1 over Weeks 1-52.
02
Drugs
salmeterol + fluticasonefluticasone propionate
03
Conditions
asthma
Beyond the preview
Go deeper on 2015-004883-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004883-12.